Get the Stockscreener App
7.53
3.95%
-0.31
Rapt Therapeutics Inc stock is traded at $7.53, with a volume of 86,002.
It is down -3.95% in the last 24 hours and up +12.25% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$7.84
Open:
$7.35
24h Volume:
86,002
Relative Volume:
0.74
Market Cap:
$145.52M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-2.4689
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-14.43%
1M Performance:
+12.25%
6M Performance:
+15.07%
1Y Performance:
-70.49%
1-Day Range:
$6.88
$7.79
1-Week Range:
$6.88
$9.112
52-Week Range:
$5.6652
$30.60
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
7.57 | 145.52M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.83 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.65 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.67 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.30 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.43 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know - Yahoo Finance
RAPT Therapeutics Executes 1-for-8 Reverse Stock Split - TipRanks
RAPT Therapeutics (RAPT) Trading Halted as News Awaits Release | RAPT Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split - Yahoo Finance
# RAPT Therapeutics to implement 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025 - Nasdaq
RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday - marketscreener.com
RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split - marketscreener.com
RAPT Therapeutics Announces Reverse Stock Split Effective June 2025 | RAPT Stock News - GuruFocus
# RAPT Therapeutics to implement 1-for-8 reverse stock split - Investing.com
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - GlobeNewswire
RAPT Therapeutics Announces Major Share Consolidation: 132M Shares Shrinking to 16.5M in Reverse Split - Stock Titan
Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Transcript : RAPT Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - marketscreener.com
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
RAPT Therapeutics Announces Development Plans for RPT904 - TipRanks
Jane Street Group LLC Sells 29,821 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Nuveen Asset Management LLC Buys 39,216 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics (RAPT) Has a New Rating from Clear Street - The Globe and Mail
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position By Stocktwits - Investing.com India
Clear Street initiates Rapt Therapeutics stock with buy rating By Investing.com - Investing.com UK
Clear Street Initiates Coverage on Rapt Therapeutics (RAPT) with Buy Rating | RAPT Stock News - GuruFocus
Millennium Management LLC Sells 222,261 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
RAPT Therapeutics Management to Share Latest Immunology Pipeline Updates at Major Healthcare Conferences - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
RAPT Therapeutics Faces Nasdaq Delisting Notice - TipRanks
What is HC Wainwright’s Forecast for RAPT Q2 Earnings? - Defense World
UBS Group Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $1.00 - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright - Defense World
D. E. Shaw & Co. Inc. Sells 278,173 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Stock: HC Wainwright & Co. Announces New Price Target | RAP - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Stock News - GuruFocus
RAPT Analyst Update: UBS Adjusts Price Target to $1 | RAPT Stock News - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outl - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outlook | RAPT Stock News - GuruFocus
UBS cuts Rapt Therapeutics stock target to $1 from $2 By Investing.com - Investing.com UK
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
RAPTRapt Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):